Neutralizing antibodies to 500 μg interferon beta-1b: 28-month results of the IDEAS extension trial

Abstract

The Interferon Dose Escalation Assessment of Safety extension trial monitored neutralizing antibodies to interferon beta-1b in patients who currently or had previously received the double dose (500 μg) for up to 28 months. Fifteen patients entered the extension trial; five patients were neutralizing antibody-positive at the start of the trial. The present study demonstrates that when neutralizing antibodies develop in patients receiving higher doses of interferon beta-1b they tend to persist for a prolonged period, although neutralizing antibody titers tend to decrease over time and some patients may revert to neutralizing antibody-negative status.

Keywords

multiple sclerosis interferon beta neutralizing antibody relapsing-remitting Betaseron interferon beta-1b

Get full access to this article

View all access options for this article.

References

Malucchi S. , Sala A. , Gilli F. , et al. Neutralizing antibodies reduce the efficacy of {beta}IFN during treatment of multiple sclerosis. Neurology 2004; 62: 2031-2037.

Goodin DS , Frohman EM , Hurwitz B. , et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology . Neurology 2007; 68: 977-984.

Gottesman MH , Friedman-Urevich S. Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS). Mult Scler 2006; 12: 271-280.

Sorensen PS , Koch-Henriksen N. , Ross C. , Clemmesen KM , Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33-39.

The IFNB Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-894.

Francis GS , Rice GP , Alsop JC Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65: 48-55.

Kappos L. , Clanet M. , Sandberg-Wollheim M. , et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005; 65: 40-47.